Hype or Hope—Combination Therapies for Lung Cancer
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Thoracic Oncology".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 127
Special Issue Editor
Special Issue Information
Dear Colleagues,
This issue looks to explore the progress and future potential of combination therapies in lung cancer. From chemo-immunotherapy to combined immunotherapies to combining different modalities of therapy it will seek to explore how these have changed and are seeking change the treatment of lung cancer. In this Special Issue, original research articles and reviews about combination therapies in patients with lung cancer are welcome.
I look forward to receiving your contributions.
Dr. Daniel Breadner
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- NSCLC
- chemo-immunotherapy
- immunotherapy
- chemoradiation
- SCLC
- combination therapies
- duo-immunotherapy
- targeted therapy
